Landos Biopharma Performance
| LABPDelisted Stock | USD 4.02 0.15 3.60% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Landos Biopharma are completely uncorrelated. Landos Biopharma right now secures a risk of 0.0%. Please verify Landos Biopharma accumulation distribution and price action indicator , to decide if Landos Biopharma will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Landos Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Landos Biopharma is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 36.6 M |
Landos |
Landos Biopharma Relative Risk vs. Return Landscape
If you would invest 402.00 in Landos Biopharma on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Landos Biopharma or generate 0.0% return on investment over 90 days. Landos Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Landos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Landos Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Landos Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Landos Biopharma, and traders can use it to determine the average amount a Landos Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LABP |
Based on monthly moving average Landos Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Landos Biopharma by adding Landos Biopharma to a well-diversified portfolio.
Landos Biopharma Fundamentals Growth
Landos Stock prices reflect investors' perceptions of the future prospects and financial health of Landos Biopharma, and Landos Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Landos Stock performance.
| Return On Equity | -0.71 | |||
| Return On Asset | -0.39 | |||
| Current Valuation | 42.67 M | |||
| Shares Outstanding | 3.13 M | |||
| Price To Book | 2.11 X | |||
| Price To Sales | 2.37 X | |||
| EBITDA | (22.73 M) | |||
| Cash And Equivalents | 55.75 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 27 K | |||
| Book Value Per Share | 7.43 X | |||
| Cash Flow From Operations | (20.48 M) | |||
| Earnings Per Share | (4.00) X | |||
| Total Asset | 38.04 M | |||
| Retained Earnings | (155.36 M) | |||
About Landos Biopharma Performance
Assessing Landos Biopharma's fundamental ratios provides investors with valuable insights into Landos Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Landos Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia. Landos Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.Things to note about Landos Biopharma performance evaluation
Checking the ongoing alerts about Landos Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Landos Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Landos Biopharma is not yet fully synchronised with the market data | |
| Landos Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (21.93 M) with profit before overhead, payroll, taxes, and interest of 18 M. | |
| Landos Biopharma currently holds about 55.75 M in cash with (20.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. |
- Analyzing Landos Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Landos Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Landos Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Landos Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Landos Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Landos Biopharma's stock. These opinions can provide insight into Landos Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Landos Stock
If you are still planning to invest in Landos Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Landos Biopharma's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |